# Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia

> **NCT01788020** · PHASE3 · COMPLETED · sponsor: **University of Ulm** · enrollment: 202 (actual)

## Conditions studied

- Waldenström's Macroglobulinemia

## Interventions

- **DRUG:** Dexamethasone, Rituximab, Cyclophosphamide
- **DRUG:** Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib

## Key facts

- **NCT ID:** NCT01788020
- **Lead sponsor:** University of Ulm
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2018-11
- **Final completion:** 2024-04
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2024-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01788020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01788020, "Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01788020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*